Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes
The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized ste...
Gespeichert in:
| Veröffentlicht in: | Cell stem cell 2023-05, Vol.30 (5), p.530-548 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 548 |
|---|---|
| container_issue | 5 |
| container_start_page | 530 |
| container_title | Cell stem cell |
| container_volume | 30 |
| creator | Hogrebe, Nathaniel J. Ishahak, Matthew Millman, Jeffrey R. |
| description | The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.
Stem cell-derived islets (SC-islets) have the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. Here, we review the most recent developments associated with generating highly functional SC-islets, solving the immune rejection problem, and overcoming practical challenges associated with SC-islet transplantation. |
| doi_str_mv | 10.1016/j.stem.2023.04.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2810915711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1934590923001200</els_id><sourcerecordid>2810915711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-70424bd4175bf84b44b172837ebcc8d9e7dc4d11623bdf75252406063f2b6e753</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMorl9_wIPk6KV1kqZNC17EbxC8KHgLTTLVLP0yyS7sv7dlV4-eZg7PvMz7EHLOIGXAiqtlGiJ2KQeepSBSAL5Hjlgp86SSUu5Pe5WJJK-gWpDjEJYAuWQgD8kik0wUuayOyMcdrrEdxg77GKjr6RxJDbZtYtG7NVrqQouRehzb2uDM0fiFvh43tBk8jR7r6PpPGjcjUkatqzVGDKfkoKnbgGe7eULeH-7fbp-Sl9fH59ubl8QIgJhIEFxoK5jMdVMKLYRmkpeZRG1MaSuU1gjLWMEzbRuZ85wLKKDIGq4LlHl2Qi63uaMfvlcYoupcmP-vexxWQfGSQcWm4mxC-RY1fgjBY6NG77rabxQDNRtVSzXXV7NRBUJNRqeji13-Sndo_05-FU7A9RbAqeXaoVfBOOwNWufRRGUH91_-D4DLh34</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2810915711</pqid></control><display><type>article</type><title>Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes</title><source>MEDLINE</source><source>Cell Press Free Archives</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hogrebe, Nathaniel J. ; Ishahak, Matthew ; Millman, Jeffrey R.</creator><creatorcontrib>Hogrebe, Nathaniel J. ; Ishahak, Matthew ; Millman, Jeffrey R.</creatorcontrib><description>The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.
Stem cell-derived islets (SC-islets) have the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. Here, we review the most recent developments associated with generating highly functional SC-islets, solving the immune rejection problem, and overcoming practical challenges associated with SC-islet transplantation.</description><identifier>ISSN: 1934-5909</identifier><identifier>EISSN: 1875-9777</identifier><identifier>DOI: 10.1016/j.stem.2023.04.002</identifier><identifier>PMID: 37146579</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>bioreactors ; Cell Differentiation ; clinical trials ; CRISPR ; critical quality attributes ; cryopreservation ; diabetes ; Diabetes Mellitus, Type 1 - therapy ; differentiation ; distribution ; encapsulation ; Humans ; immune tolerance ; insulin ; Insulin-Secreting Cells ; Islets of Langerhans ; pancreas ; Pluripotent Stem Cells ; safety ; SC-islets ; scale-up ; single-cell sequencing ; stem cells ; stress ; therapy ; transplantation</subject><ispartof>Cell stem cell, 2023-05, Vol.30 (5), p.530-548</ispartof><rights>2023 The Author(s)</rights><rights>Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-70424bd4175bf84b44b172837ebcc8d9e7dc4d11623bdf75252406063f2b6e753</citedby><cites>FETCH-LOGICAL-c400t-70424bd4175bf84b44b172837ebcc8d9e7dc4d11623bdf75252406063f2b6e753</cites><orcidid>0000-0003-0426-3492</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.stem.2023.04.002$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37146579$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hogrebe, Nathaniel J.</creatorcontrib><creatorcontrib>Ishahak, Matthew</creatorcontrib><creatorcontrib>Millman, Jeffrey R.</creatorcontrib><title>Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes</title><title>Cell stem cell</title><addtitle>Cell Stem Cell</addtitle><description>The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.
Stem cell-derived islets (SC-islets) have the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. Here, we review the most recent developments associated with generating highly functional SC-islets, solving the immune rejection problem, and overcoming practical challenges associated with SC-islet transplantation.</description><subject>bioreactors</subject><subject>Cell Differentiation</subject><subject>clinical trials</subject><subject>CRISPR</subject><subject>critical quality attributes</subject><subject>cryopreservation</subject><subject>diabetes</subject><subject>Diabetes Mellitus, Type 1 - therapy</subject><subject>differentiation</subject><subject>distribution</subject><subject>encapsulation</subject><subject>Humans</subject><subject>immune tolerance</subject><subject>insulin</subject><subject>Insulin-Secreting Cells</subject><subject>Islets of Langerhans</subject><subject>pancreas</subject><subject>Pluripotent Stem Cells</subject><subject>safety</subject><subject>SC-islets</subject><subject>scale-up</subject><subject>single-cell sequencing</subject><subject>stem cells</subject><subject>stress</subject><subject>therapy</subject><subject>transplantation</subject><issn>1934-5909</issn><issn>1875-9777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMorl9_wIPk6KV1kqZNC17EbxC8KHgLTTLVLP0yyS7sv7dlV4-eZg7PvMz7EHLOIGXAiqtlGiJ2KQeepSBSAL5Hjlgp86SSUu5Pe5WJJK-gWpDjEJYAuWQgD8kik0wUuayOyMcdrrEdxg77GKjr6RxJDbZtYtG7NVrqQouRehzb2uDM0fiFvh43tBk8jR7r6PpPGjcjUkatqzVGDKfkoKnbgGe7eULeH-7fbp-Sl9fH59ubl8QIgJhIEFxoK5jMdVMKLYRmkpeZRG1MaSuU1gjLWMEzbRuZ85wLKKDIGq4LlHl2Qi63uaMfvlcYoupcmP-vexxWQfGSQcWm4mxC-RY1fgjBY6NG77rabxQDNRtVSzXXV7NRBUJNRqeji13-Sndo_05-FU7A9RbAqeXaoVfBOOwNWufRRGUH91_-D4DLh34</recordid><startdate>20230504</startdate><enddate>20230504</enddate><creator>Hogrebe, Nathaniel J.</creator><creator>Ishahak, Matthew</creator><creator>Millman, Jeffrey R.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0426-3492</orcidid></search><sort><creationdate>20230504</creationdate><title>Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes</title><author>Hogrebe, Nathaniel J. ; Ishahak, Matthew ; Millman, Jeffrey R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-70424bd4175bf84b44b172837ebcc8d9e7dc4d11623bdf75252406063f2b6e753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>bioreactors</topic><topic>Cell Differentiation</topic><topic>clinical trials</topic><topic>CRISPR</topic><topic>critical quality attributes</topic><topic>cryopreservation</topic><topic>diabetes</topic><topic>Diabetes Mellitus, Type 1 - therapy</topic><topic>differentiation</topic><topic>distribution</topic><topic>encapsulation</topic><topic>Humans</topic><topic>immune tolerance</topic><topic>insulin</topic><topic>Insulin-Secreting Cells</topic><topic>Islets of Langerhans</topic><topic>pancreas</topic><topic>Pluripotent Stem Cells</topic><topic>safety</topic><topic>SC-islets</topic><topic>scale-up</topic><topic>single-cell sequencing</topic><topic>stem cells</topic><topic>stress</topic><topic>therapy</topic><topic>transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hogrebe, Nathaniel J.</creatorcontrib><creatorcontrib>Ishahak, Matthew</creatorcontrib><creatorcontrib>Millman, Jeffrey R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cell stem cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hogrebe, Nathaniel J.</au><au>Ishahak, Matthew</au><au>Millman, Jeffrey R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes</atitle><jtitle>Cell stem cell</jtitle><addtitle>Cell Stem Cell</addtitle><date>2023-05-04</date><risdate>2023</risdate><volume>30</volume><issue>5</issue><spage>530</spage><epage>548</epage><pages>530-548</pages><issn>1934-5909</issn><eissn>1875-9777</eissn><abstract>The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.
Stem cell-derived islets (SC-islets) have the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. Here, we review the most recent developments associated with generating highly functional SC-islets, solving the immune rejection problem, and overcoming practical challenges associated with SC-islet transplantation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37146579</pmid><doi>10.1016/j.stem.2023.04.002</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0003-0426-3492</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1934-5909 |
| ispartof | Cell stem cell, 2023-05, Vol.30 (5), p.530-548 |
| issn | 1934-5909 1875-9777 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2810915711 |
| source | MEDLINE; Cell Press Free Archives; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present) |
| subjects | bioreactors Cell Differentiation clinical trials CRISPR critical quality attributes cryopreservation diabetes Diabetes Mellitus, Type 1 - therapy differentiation distribution encapsulation Humans immune tolerance insulin Insulin-Secreting Cells Islets of Langerhans pancreas Pluripotent Stem Cells safety SC-islets scale-up single-cell sequencing stem cells stress therapy transplantation |
| title | Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A39%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developments%20in%20stem%20cell-derived%20islet%20replacement%20therapy%20for%20treating%20type%201%20diabetes&rft.jtitle=Cell%20stem%20cell&rft.au=Hogrebe,%20Nathaniel%20J.&rft.date=2023-05-04&rft.volume=30&rft.issue=5&rft.spage=530&rft.epage=548&rft.pages=530-548&rft.issn=1934-5909&rft.eissn=1875-9777&rft_id=info:doi/10.1016/j.stem.2023.04.002&rft_dat=%3Cproquest_cross%3E2810915711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2810915711&rft_id=info:pmid/37146579&rft_els_id=S1934590923001200&rfr_iscdi=true |